Picture Consultech GmbH Secure Funding with RnD Grants v7 650x100px
Document › Details

Cevec Pharmaceuticals GmbH. (2/9/17). "Press Release: Cevec Licenses CAP Technologies for the Development and Commercialization of Vaccines against Zika Virus Infections". Cologne.

Organisations Organisation Cevec Pharmaceuticals GmbH
  Group Danaher (Group)
  Organisation 2 NewLink Genetics Corporation (Nasdaq: NLNK)
Products Product CAP®GT cell line
  Product 2 Zika vaccine
Index term Index term NewLink Genetics–Cevec: rec protein production technology, 201702– license €na to CAP GT + CAP Go cell lines for Zika vaccine developm + commerc
Persons Person Ubags, Frank (Cevec 201504– CEO before COO since 201409 before Coral BioNet + Scil Proteins + Kiadis + Rhein Biotech)
  Person 2 Hennecke, Anne (MC Services 201211 Managing Partner before Evotec + Schwarz Pharma)

Agreement marks an important step in establishing CAP® technologies as the new global industrial standard for viral vector and vaccine development

CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced that it has signed an exclusive license agreement with NewLink Genetics (NASDAQ:NLNK) for use of its proprietary CAP®GT and CAP®Go cell lines in the development and commercialization of products for the treatment and prophylaxis of Zika virus infections.

Under the terms of the agreement, CEVEC will grant NewLink Genetics and its affiliates the rights to research, develop, manufacture and commercialize CAP®GT and/or CAP®Go derived Zika vaccine candidates. Financial details of the agreement were not disclosed.

“NewLink is an important player with significant experience in developing immuno-oncology product candidates and vaccines in infectious diseases with several products in clinical development. The joint agreement is a strong endorsement of our CAP® system and represents another important step towards establishing CEVEC’s technologies as the new global industry standard for viral vector and vaccine development,” commented Frank Ubags, CEO of CEVEC. “Outstanding yields, scalability, excellent documentation and regulatory status, including a referenceable U.S. FDA Biologics Master File increasingly convince the biopharmaceutical industry to embark on the CAP® technologies. We’re proud and excited to see our technologies significantly contributing to the development of a steadily growing number of innovative gene therapy and vaccine applications including a vaccine solution that will address the threat of Zika virus disease.”

About Zika:

Often causing no or only mild symptoms, similar to a very mild form of dengue fever in adults, the infection known as Zika fever or Zika virus disease can spread from a pregnant woman to her fetus. This can result in microcephaly, brain malformations, and other severe fetal birth defects. As of 2016, the illness cannot be prevented by medications or vaccines. Zika is spread by daytime-active Aedes mosquitoes and can also be transmitted from men and women to their sexual partners.

About CEVEC:

CEVEC is a center of expertise for the production of biopharmaceuticals using a unique human cell-based expression system.

CAP®GT is a regulatory endorsed expression platform for scalable viral vector production. CEVEC has successfully developed CAP®GT suspension cell-derived viral packaging and producer cell lines which enable better scale-up and competitive production costs when compared to adherent cell culture systems. CAP®GT suspension cell lines grow to high cell densities and show a broad viral propagation spectrum. Gene therapy vectors such as lentivirus (LV), adenovirus (AV) and adeno-associated virus (AAV) can be produced at industrial scale.

CAP®Go enables the production of proteins previously out of reach representing a significant proportion of the human proteome that is notoriously difficult to express in conventional cell lines such as CHO. The CAP®Go expression platform comprises a portfolio of glyco-optimized human suspension cell lines for the highly efficient production of a broad range of difficult to express recombinant proteins with authentic human post-translational modifications or on demand tailor made glycosylation patterns.

Follow CEVEC on LinkedIn.


CEVEC Pharmaceuticals GmbH
Dr. Nico Scheer
Chief Business Officer
T.:+49 221 46020800

MC Services AG
Anne Hennecke
Public Relations
T.: +49 211 52925222

Record changed: 2023-06-05


Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Danaher (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group World of Partnering Opportunities 650x300px

» top